ArticleCell metabolism2018
CD38-NAD
Open access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers.
0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed
14.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 254 citations in OpenAlex.
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.International journal of molecular sciences · 2021Trial
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- CD38-activated macrophages drive age-related placental senescence by depleting NADNature communications · 2026Article
- Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Endogenous metabolite signaling orchestrates tumor immune evasion.Cell insight · 2026Review
- Emerging chemical strategies for CD38 inhibition: restoring NADBioorganic & medicinal chemistry · 2026Review
- T-Cell Exhaustion in the Tumor Microenvironment: Subcellular Dysfunction, Pan-Cancer Characteristics, and Therapeutic Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Contextualizing TNature reviews. Immunology · 2026Review
- Depletion of the RNA-Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring.Translational oncology · 2026Article
- Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases.Cell communication and signaling : CCS · 2026Review
- CD38 expression by neonatal human naive CD4+ T cells shapes their distinct metabolic and tolerogenic properties.The Journal of clinical investigation · 2026Article
- Endothelial NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- Peripheral Immune Remodeling After Spinal Cord Injury: Marked by Expansion of CD38Neurology(R) neuroimmunology & neuroinflammation · 2026Observational
- Cytoplasmic NAD/H synthesis via NRK1 regulates inflammatory capacity and promotes survival of CD4Nature communications · 2026Article
- Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.Frontiers in immunology · 2026Article
- Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-ϒ reprograms tumor-associated macrophages to suppress triple negative breast cancer.Breast cancer research : BCR · 2025Article
- CD38-NAD(+) Axis: New Insights into Glaucoma Therapy.Molecular neurobiology · 2025Review
- DOCK2 modulates immune checkpoint inhibitor responsiveness and prognosis in cutaneous melanoma through multi-omics and single-cell T cell dynamics profiling.Discover oncology · 2025Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 5 institutions in 1 country.
Shilpak ChatterjeeDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Anusara DaenthanasanmakDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Paramita ChakrabortyDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Megan W WyattDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Payal DharDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Shanmugam Panneer SelvamDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Jianing FuDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Jinyu ZhangDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Hung NguyenDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Inhong KangDepartment of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Kyle TothDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Mazen Al-HomraniDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Mahvash HusainDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Gyda BeesonDepartment of Pharmaceutical and Biomedical Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Lauren BallDepartment of Pharmaceutical and Biomedical Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Kristi HelkeDepartment of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Shahid HusainDepartment of Ophthalmology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Elizabeth Garrett-MayerDepartment of Public Health, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Gary HardimanDepartment of Nephrology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Meenal MehrotraDepartment of Pathology and Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Michael I NishimuraDepartment of Surgery, Loyola University, Maywood, IL 60153, USA.
Craig C BeesonDepartment of Pharmaceutical and Biomedical Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Melanie Gubbels BuppRandolph-Macon College, Ashland, VA 23005, USA.
Jennifer WuDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Besim OgretmenDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Chrystal M PaulosDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Jeffery RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN 37232, USA.
Xue-Zhong YuDepartment of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Shikhar MehrotraDepartment of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: mehrotr@musc.edu.
MUSC Hollings Cancer Center · USMedical University of South Carolina · USAshland (United States) · USLoyola University Chicago · USVanderbilt University · US
Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MSOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2012 to 2020
$20.2MTCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPYP01CA154778 · NCI · LOYOLA UNIVERSITY CHICAGO · PI NISHIMURA, MICHAEL I. · 2011 to 2015
$15.4MProject 3: Targeting SK2/S1P Signaling for the Regulation of c-Myc and Tumor SuppressionP01CA203628 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BIELAWSKA, ALICJA · 2016 to 2021
$8.9MResearch Supplement to Promote Diversity in Health-Related ResearchR01CA214461 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Besim Ogretmen · 2018 to 2026
$3.3MTarget MIC shedding to revive anti-tumor immunityR01CA204021 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JENNIFER D · 2016 to 2022
$1.8MNKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancerR01CA208246 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JENNIFER D · 2016 to 2020
$1.8MOxidative stress and AICD in memory T cell persistenceR01CA138930 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2010 to 2014
$1.5MOrbitrap Mass SpectrometerS10OD010731 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2012 to 2012
$600kIsolation and Characterization of Prostrate Antigen Specific High Affinity TCRR21CA137725 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2009 to 2010
$357kNCI NIH HHS P01 CA154778NCI NIH HHS P01 CA203628NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA138930NCI NIH HHS R01 CA204021NCI NIH HHS R01 CA208246NCI NIH HHS R01 CA214461NCI NIH HHS R21 CA137725NIDDK NIH HHS P30 DK058404NIGMS NIH HHS P20 GM103542NIH HHS S10 OD010731
Abstract
Heightened effector function and prolonged persistence, the key attributes of Th1 and Th17 cells, respectively, are key features of potent anti-tumor T cells. Here, we established ex vivo culture conditions to generate hybrid Th1/17 cells, which persisted long-term in vivo while maintaining their effector function. Using transcriptomics and metabolic profiling approaches, we showed that the enhanced anti-tumor property of Th1/17 cells was dependent on the increased NAD
Indexed as
ImmunotherapyADP-ribosyl Cyclase 1AnimalsForkhead Box Protein O1GlutamineMice, Inbred C57BLNADNeoplasmsSirtuin 1Th17 CellsTh1 CellsT-LymphocytesADP-ribosyl Cyclase 1Forkhead Box Protein O1Foxo1 protein, mouseGlutamineNADSirtuin 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.